The project starts out with an initial investment of £5m from each partner over a three year period.
The collaboration between two UK based pharmaceutical companies, GSK and AstraZeneca, and The University of Manchester will bring together scientists from both the pharmaceutical industry and academia to work collaboratively on inflammation research and translational medicine.
Such advances are expected to benefit people affected by diseases associated with chronic inflammation, including asthma, chronic obstructive pulmonary disease, rheumatoid arthritis and inflammatory bowel disease.
The University of Manchester VP and Faculty of Medical and Human Sciences dean Ian Jacobs said the collaboration builds on the mutual understanding developed between the university and both GSK and AstraZeneca over recent years, and will bring together expertise in biomedical research from the university with the resources and drug discovery expertise from GSK and AstraZeneca to create true partnership and synergy.